Sign in

CIK 0001178670 · Large accelerated filer

ALNYLAM PHARMACEUTICALS, INC.

Sign in to watch
Ticker
ALNY
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
operating
EIN
770602661
Phone
(617) 551-8200
Business address
675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
Former names
ALNYLAM PHARMACEUTICALS INC
Open-market buys, last 90 days
$543,126
in 2 filings
Open-market sales, last 90 days
$398,855
in 1 filing

Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2025-05-08 Bertozzi Carolyn R Director Grant or award +775 775
2025-05-08 Bertozzi Carolyn R Director Grant or award · Stock Option (right to buy) +1,558 1,558
2025-05-02 Greenstreet Yvonne Chief Executive Officer Gift −41,311 57,324
2025-04-16 Reitan Colleen F Director Sale −36 $232.86 $8K 0
2025-03-24 Garg Pushkal CMO & EVP Dev & Med Affairs Option exercise 10b5-1 +5,445 $42.22 $230K 25,666
2025-03-24 Garg Pushkal CMO & EVP Dev & Med Affairs Sale 10b5-1 −5,445 $300.00 $1.6M 20,221
2025-03-24 Garg Pushkal CMO & EVP Dev & Med Affairs Option exercise · Stock Option (right to buy) 10b5-1 −5,445 0
2025-03-24 PYOTT DAVID E I Director Option exercise 10b5-1 +7,440 $88.95 $662K 7,576
2025-03-24 PYOTT DAVID E I Director Sale 10b5-1 −7,440 $299.00 $2.2M 136
2025-03-24 PYOTT DAVID E I Director Option exercise · Stock Option (right to buy) 10b5-1 −7,440 0
2025-03-21 Garg Pushkal CMO & EVP Dev & Med Affairs Sale 10b5-1 −4,321 $285.00 $1.2M 20,221
2025-03-13 SCHULMAN AMY W Director Option exercise +2,750 $131.21 $361K 11,186
2025-03-13 SCHULMAN AMY W Director Option exercise · Stock Option (right to buy) −2,750 0
2025-03-04 Fitzgerald Kevin Joseph CSO & EVP, Head of Research Sale 10b5-1 −121 $239.24 $29K 14,224
2025-03-04 Fitzgerald Kevin Joseph CSO & EVP, Head of Research Sale 10b5-1 −328 $240.95 $79K 13,896
2025-03-04 Fitzgerald Kevin Joseph CSO & EVP, Head of Research Sale 10b5-1 −324 $241.68 $78K 13,572
2025-03-04 Fitzgerald Kevin Joseph CSO & EVP, Head of Research Sale 10b5-1 −71 $242.93 $17K 13,501
2025-03-04 Garg Pushkal CMO & EVP Dev & Med Affairs Sale 10b5-1 −147 $239.25 $35K 25,203
2025-03-04 Garg Pushkal CMO & EVP Dev & Med Affairs Sale 10b5-1 −343 $240.92 $83K 24,860
2025-03-04 Garg Pushkal CMO & EVP Dev & Med Affairs Sale 10b5-1 −198 $241.60 $48K 24,662

Page 30 of 41 · 816 trades